Update on management of pediatric atopic dermatitis

Abstract

Atopic dermatitis is the most common chronic inflammatory skin disease in children. It usually develops in infancy and early child hood and is an entry point of ‘atopic march’, which may progress to other allergic diseases, including allergic rhinitis and asthma. Al though there is no disagreement on the importance of early treatment of atopic dermatitis, it is difficult to treat children with mod erate to severe atopic dermatitis due to concerns about treatment-related side effects and age restrictions for effective drugs in real world. As recent researches have extend our understanding of pathogenesis, new agents targeted key pathologic mechanisms have been developed. Therefore, it is time to establish a new paradigm of treatment for children with atopic dermatitis since new biologics have been demonstrated to be effective and safe in children. The objective of this article is to review the clinical character istics, severity classification, pathogenesis, and treatment, in particular, biologics already approved/undergoing clinical trials for chil dren with atopic dermatitis. (Allergy Asthma Respir Dis 2021;9:59-68)